D a as Treatment for Hepatocellular Carcinoma

D a as are used together in two drug combinations in order to prevent drug resistance. Cure rates are greater than 95 % in the majority of infected individuals. Liver transplant may be indicated before h c v therapy and those with decompensation or hepato cellular carso noma. The side affect profile of d a as is much better than that of interferent base regiments.